Direct MHRA licensing of medical devices: an enabling power in the health bill

An enabling power, not a settled pathway

According to BioSlice Blog’s Virtual and Digital Health Digest for October 2026, the UK health bill includes an enabling power for a future medical device licensing regime. The digest reports that this could allow the Medicines and Healthcare products Regulatory Agency (MHRA) to assess and license devices directly, rather than relying on third-party UK approved bodies.

The distinction between an enabling power and an operational route is central to understanding the reported proposal. BioSlice Blog describes a framework whose details would be left to subsequent regulations. Its account should therefore not be read as confirmation that a direct licensing pathway is already available, or that its practical requirements have been settled.

What direct assessment could mean

As reported by BioSlice Blog, the potential change concerns who could assess and license a device. Direct assessment by the MHRA would represent a different route from reliance on third-party UK approved bodies. However, it is not yet clear how that route would interact with existing arrangements, or whether access would be limited to particular circumstances or device categories.

For surgeons involved in device development and clinical translation, the proposal raises questions about the future route from development to market. Those questions include which technologies might be eligible, what an application would involve and how responsibilities would be divided. These remain open questions, rather than established features of the potential regime described by BioSlice Blog.

Software and AI within scope

BioSlice Blog reports that the potential licensing regime would include software- and AI-enabled medical devices. This gives the proposal relevance beyond devices defined principally by their physical components. However, the reported inclusion of these technologies does not itself establish a separate assessment standard or a distinct process for AI-enabled products.

It is not yet clear what evidence requirements, review stages or ongoing obligations would apply to such devices under a direct licensing route. Nor is it clear how later regulations might distinguish between different types of software-enabled technology. BioSlice Blog’s account places the detailed design of the regime in future regulations, so expectations about its operation remain provisional.

Updating rules and sharing information

Alongside the potential licensing power, BioSlice Blog reports proposed changes to regulatory updating processes and clearer MHRA information-sharing powers. These are separate elements of the reported bill, although they sit within the same broader account of potential regulatory change.

The practical effect of those provisions is not yet clear from the information available. Questions remain about how updating processes would work and what the information-sharing provisions would cover in practice. The reported proposals alone do not establish particular consequences for individual development projects or technologies.

What remains unresolved

The central development reported by BioSlice Blog is a proposed power to create a regime, rather than a fully specified licensing service. Eligibility, timing, procedural requirements and the relationship with UK approved bodies are not yet clear. There is also no basis in the supplied account for assuming shorter assessments, lower costs or a particular effect on market access.

For readers following surgical innovation, the distinction is between the possibility of a new regulatory route and the detail needed to understand its operation. According to BioSlice Blog, that detail would come through later regulations.

This article is an overview for information only; readers should consult the original sources and appropriate professional guidance.